Important Correction of Drug Information

ACTION REQUIRED

July 14, 2017

Subject: Incorrect osmolarity concentration on Sodium Phosphates Injections, USP labeling

15 mL Single Dose
Sodium Phosphates Injection, USP

NDC	Lot Number	Expiration Date	Strength	Configuration/Count
0409-7391-72	See Appendix A for Affected Lots	See Appendix A	45 mM P/15 mL (3 mM P/mL) 60 mEq Na^+/15mL (4.0 mEq/mL)	25 Vials per Tray, 4 Trays per Case

Dear Health Care Provider,

Hospira, Inc., a Pfizer company, ("Hospira"), recently became aware of an error in the labeling of **Sodium Phosphates Injection, USP.** The Primary (Vial) labeling, Package Insert and Tray labeling each reference an incorrect osmolarity concentration of 12 mOsmol/mL as illustrated in the photograph below. The correct calculated osmolarity is **7** mOsmol/mL.



Please note that all other information, including the product strength information (3mMol of Phosphorus and 4 mEq of Sodium) is correct on all labeling, and there are no known quality issues with this product. Hospira conducted a Health Hazard Assessment, which concluded that the potential risk to patients associated with this issue is extremely low, with no clinically significant consequence.

The impacted product lots were distributed between August 2015 through May 2017.

Hospira, Inc., a Pfizer company
275 North Field Drive
Lake Forest, IL 60045
(224) 212-2000
www.pfizerinjectables.com

Recommendations to Health Care Professionals and Wholesalers:

It is not necessary to return the product, however it is important that this information be provided to all appropriate staff. If you have further distributed this product to any other accounts, please communicate this information to those accounts immediately. Please respond to this notification even if you do not have affected product. To respond, complete the requested information on the attached Business Reply Card (BRC) and return it as directed within five (5) Business days. Should you have any questions about responding to this notification or require additional copies of this letter, please contact Stericycle at 1-800-805-3093 (Mon.-Fri. 8am-5pm ET).

Please contact Pfizer Customer Service at 1-844-646-4398 (Mon.-Fri. 8am-7pm ET) or your Pfizer representative for any questions you may have regarding this market action.

This Important Drug Information is being shared with the knowledge of the Food and Drug Administration. Your immediate attention and assistance is greatly appreciated. We sincerely regret any inconvenience this may have caused.

If you have any medical questions regarding this product, please contact Pfizer Medical Information at 1-800-615-0187 (Mon.-Fri. 8am-7pm ET).

Reporting Adverse Events

To report suspected adverse reactions, contact Pfizer Inc. at 1-800-438-1985.

Adverse events or quality problems experienced with the use of this product may also be reported to the FDA's MedWatch Adverse Event Reporting Program either online, or regular mail, or by fax:

- Complete and submit the report Online: www.fda.gov/medwatch/report.htm

Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

You may contact Pfizer Medical Information at 1-800-615-0187 (Mon.-Fri. 8am-7pm ET) if you have any questions about the information contained in this letter or the safe and effective use of Sodium Phosphates Injection, USP. This letter is not intended as a complete description of the benefits and risks related to the use of Sodium Phosphates Injection, USP. Please refer to the enclosed Full Prescribing Information. The Full Prescribing Information is available at www.pfizer.com/products/product-detail/sodium_phosphates.

Sincerely,

Michele Rath
Sr. Manager, Premixes and Micronutrients, Product Portfolio
Pfizer Essential Health

Hospira, Inc., a Pfizer company
275 North Field Drive
Lake Forest, IL 60045
(224) 212-2000
www.pfizerinjectables.com

Appendix A -
Impacted Lots of NDC 0409-7391-72

Lot Number	Expiry Date
57248DK	1SEP2017
57249DK	1SEP2017
57349DK	1SEP2017
57356DK	1SEP2017
57357DK	1SEP2017
58078DK	1OCT2017
58079DK	1OCT2017
59067DK	1NOV2017
59249DK	1NOV2017
59332DK	1NOV2017
59397DK	1NOV2017
61281DK	1JAN2018
62472DK	1FEB2018
63120DK	1MAR2018
63223DK	1MAR2018
63225DK	1MAR2018
63476DK	1MAR2018
63478DK	1MAR2018
63487DK	1MAR2018
64147DK	1APR2018
65053DK	1MAY2018
65148DK	1MAY2018
65315DK	1MAY2018

Lot Number	Expiry Date
65437DK	1MAY2018
65451DK	1MAY2018
65500DK	1MAY2018
66078DK	1JUN2018
66184DK	1JUN2018
66441DK	1JUN2018
66485DK	1JUN2018
66489DK	1JUN2018
66498DK	1JUN2018
67292DK	1JUL2018
67293DK	1JUL2018
68110DK	1AUG2018
68302DK	1AUG2018
68378DK	1AUG2018
72246DK	1DEC2018
72247DK	1DEC2018
73195DK	1JAN2019
73260DK	1JAN2019
74355DK	1FEB2019
74356DK	1FEB2019
75037DK	1MAR2019
76291DK	1APR2019
76292DK	1APR2019

Note: lot numbers may be followed by 01 or 02

Hospira, Inc., a Pfizer company
275 North Field Drive
Lake Forest, IL 60045
(224) 212-2000
www.pfizerinjectables.com

SODIUM PHOSPHATES

Injection, USP

45 mM P in 15 mL

(3 mM P and 4 mEq Na^+/mL)

FOR ADDITIVE USE ONLY AFTER DILUTION IN I.V. FLUIDS

Plastic Vial

R_x only

DESCRIPTION

Sodium Phosphates Injection, USP, 3 mM P/mL (millimoles/mL), is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic sodium phosphate and dibasic sodium phosphate in water for injection.

The solution is administered after dilution by the intravenous route as an electrolyte replenisher. *It must not be administered undiluted.*

Each mL contains 276 mg of monobasic sodium phosphate, monohydrate and 142 mg of dibasic sodium phosphate, anhydrous (equivalent to 268 mg of dibasic sodium phosphate, heptahydrate).

One mM of phosphorus weighs 31 mg, and the product provides 93 mg (approximately 3 mM) of phosphorus/mL plus 92 mg (4 mEq) of sodium/mL. Note: 1 mM P = 1 mM PO_4. It contains no bacteriostat, antimicrobial agent or added buffer. The pH is 5.5 (5.0 to 6.0). The osmolar concentration is 7 mOsmol/mL (calc).

The solution is intended as an alternative to potassium phosphate to provide phosphorus for addition to large volume infusion fluids for intravenous use.

It is provided as a 15 mL partial fill single-dose vial; when lesser amounts are required, the unused portion should be discarded with the entire unit.

Monobasic Sodium Phosphate, USP (monohydrate) is chemically designated $NaH_2PO_4 \cdot H_2O$, white, odorless crystals or granules freely soluble in water.

Dibasic Sodium Phosphate, USP (anhydrous) is chemically designated Na_2HPO_4, colorless or white granular salt freely soluble in water.

The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.

CLINICAL PHARMACOLOGY

Phosphorus in the form of organic and inorganic phosphate has a variety of important biochemical functions in the body and is involved in many significant metabolic and enzyme reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion.

Phosphorus is present in plasma and other extracellular fluid, in cell membranes and intracellular fluid, as well as in collagen and bone tissues. Phosphorus in the extracellular fluid is primarily in inorganic form and plasma levels may vary somewhat with age. The ratio of disodium phosphate and monosodium phosphate in the extracellular fluid is 4 to 1 (80% to 20%) at the normal pH of 7.4. This buffer ratio varies with the pH, but owing to its relatively low concentration, it contributes little to the buffering capacity of the extracellular fluid.

Phosphorus, present in large amounts in erythrocytes and other tissue cells, plays a significant intracellular role in the synthesis of high energy organic phosphates. It has been shown to be essential to maintain red cell glucose utilization, lactate production, and the concentration of both erythrocyte adenosine triphosphate (ATP) and 2,3 diphosphoglycerate (DPG), and must be deemed as important to other tissue cells. Hypophosphatemia should be avoided during periods of total parenteral nutrition, or other lengthy periods of intravenous infusions. It has been suggested that patients receiving total parenteral nutrition receive 12 to 15 mM phosphorus per 250 g of dextrose. Serum phosphorus levels should be regularly monitored and appropriate amounts of phosphorus should be added to the infusions to maintain normal serum phosphorus levels. Intravenous infusion of inorganic phosphorus may be accompanied by a decrease in the serum level and urinary excretion of calcium. The normal level of serum phosphorus is 3.0 to 4.5 mg/100 mL in adults; 4.0 to 7.0 mg/100 mL in children.

Intravenously infused phosphorus not taken up by the tissues is excreted almost entirely in the urine. Plasma phosphorus is believed to be filterable by the renal glomeruli, and the major portion of filtered phosphorus (greater than 80%) is actively reabsorbed by the tubules. Many modifying influences tend to alter the amount excreted in the urine.

Sodium is the principal cation of extracellular fluid. It comprises more than 90% of the total cations at its normal plasma concentration of approximately 142 mEq/liter. While the sodium ion can diffuse across cell membranes, intracellular sodium is maintained at a much lower concentration than extracellular sodium through the expenditure of energy by the cell (so called "sodium cation pump"). Loss of intracellular potassium ion is usually accompanied by an increase in intracellular sodium ion.

When serum sodium concentration is low, the secretion of antidiuretic hormone (ADH) by the pituitary is inhibited, thereby preventing water reabsorption by the distal renal tubules. On the other hand, adrenal secretion of aldosterone increases renal tubular reabsorption of sodium in an effort to re-establish normal serum sodium concentration.

INDICATIONS AND USAGE

Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

The concomitant amount of sodium (Na^+ 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

CONTRAINDICATIONS

Sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.

WARNINGS

Sodium Phosphates Injection, USP, 3 mM P/mL must be diluted and thoroughly mixed before use.

To avoid phosphorus intoxication, infuse solutions containing sodium phosphate slowly. Infusing high concentrations of phosphorus may result in a reduction of serum calcium and symptoms of hypocalcemic tetany. Calcium levels should be monitored.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

Do not administer unless solution is clear and seal is intact. Discard unused portion.

Phosphorus replacement therapy with sodium phosphate should be guided primarily by the serum phosphorus level and the limits imposed by the accompanying sodium (Na^+) ion.

Use with caution in patients with renal impairment, cirrhosis, cardiac failure and other edematous or sodium-retaining states.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Pregnancy Category C: Animal reproduction studies have not been conducted with sodium phosphate. It is also not known whether sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium phosphate should be given to a pregnant woman only if clearly needed.

Pediatric Use: The safety and effectiveness of sodium phosphate has been established in pediatric patients (neonates, infants, children and adolescents).

Geriatric Use: An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Sodium ions and phosphorus are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

Adverse reactions involve the possibility of phosphorus intoxication. Phosphorus intoxication results in a reduction of serum calcium and the symptoms are those of hypocalcemic tetany. See WARNINGS.

OVERDOSAGE

In the event of overdosage, discontinue infusions containing sodium phosphate immediately and institute corrective therapy to restore depressed serum calcium and to reduce elevated serum sodium levels. See WARNINGS, PRECAUTIONS and ADVERSE REACTIONS.

DOSAGE AND ADMINISTRATION

Sodium Phosphates Injection, USP, 3 mM P/mL is administered intravenously *only after dilution and thorough mixing in a larger volume of fluid.* The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, phosphorus and calcium levels should be

monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles (mM) of phosphorus.

In patients on total parenteral nutrition, approximately 12 to 15 mM of phosphorus (equivalent to 372 to 465 mg elemental phosphorus) per liter bottle of TPN solution containing 250 g dextrose is usually adequate to maintain normal serum phosphorus, though larger amounts may be required in hypermetabolic states. The amount of sodium and phosphorus which accompanies the addition of sodium phosphate also should be kept in mind, and if necessary, serum sodium levels should be monitored.

The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mM P/kg/day.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

HOW SUPPLIED

Sodium Phosphates Injection, USP, 3 mM P/mL is supplied as per below.

Unit of Sale	**Concentration**	**Unit of Use**
NDC 0409-7391-72 Tray containing 25 vials	45 mM (3 mM P/mL) containing 60 mEq Na^+ (4.0 mEq/mL)	NDC 0409-7391-82 15 mL Single-dose Plastic Vial

Each container is partially filled to provide air space needed for complete vacuum withdrawal of the contents into the I.V. container.

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Hospira

HOSPIRA, INC., LAKE FOREST, IL 60045 USA

LAB-1044-2.0

Revised: 6/2017